Gabriella DiBernardo

University of California, Los Angeles
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Objective To demonstrate the significance of supercharged natural killer (sNK) cells to target aggressive gynecological tumours. Methods and analysis We used cell cultures of peripheral blood-derived mononuclear cells (PBMCs) and purified NK cells alone and in the presence of tumours. MHC-class gene expression assessments of ovarian tumours were performed using gene set enrichment analysis (GSEA). Secretion and expression levels of cytokines in PBMCs and NK cells were determined using ELISA and scRNA seq analysis, respectively. A flow cytometer was used for surface marker analysis. 51 Cr and eSight were used to determine the killing activity of NK cells. Results We have observed a significant decrease in the numbers and functions of NK cells in patients with ovarian cancer. GSEA revealed differently expressed genes, decreased differentiation- and immune-related genes, and increased genes for cell cycle analysis in recurrent tumours compared with chemo-naive ovarian tumours. Increased gene expression as well as secretion of interferon-γ and tumour necrosis factor-α and increased avidity in binding to tumour cells by sNK cells was observed. Unlike primary interleukin (IL)-2-activated NK cells, sNK cells effectively lysed OVCAR8 ovarian poorly differentiated cancer stem-like cells (PDCSCs) and well-differentiated OVCAR4 tumours. Primary ovarian tumours with lower MHC-class I expression were highly susceptible to both primary IL-2-activated NK and sNK cells, whereas the well-differentiated tumours with high expression of MHC-class I were only susceptible to sNK cells. Conclusion The use of sNK cells in immunotherapy emerges as a potentially effective strategy to target and eliminate the majority of ovarian tumour clones, thereby providing a potential therapeutic opportunity in preventing the recurrence of the disease.

Year:

2025

Adoptive cell therapy using T cells engineered to express chimeric antigen receptors (CARs) has only shown limited responses against solid tumors, and improved CAR-T cell designs are needed to achieve more potent and durable responses. One of the major factors limiting CAR-T cell activity within solid tumors is the highly immunosuppressive solid tumor microenvironment (TME) which promotes immune-cell dysfunction and tumor immune escape. Specifically, vascular endothelial growth factor A (VEGF-A) presents as a physical barrier through its pro-angiogenic properties and contribution to excessive tumor vascularization, giving rise to abnormal and dysfunctional vessels with impaired perfusion thus leading to intra-tumoral hypoxia. Furthermore, VEGF-A serves as a chemical barrier by suppressing T-cell activation and cytotoxicity, upregulating immune checkpoints on T cells, inhibiting dendritic cell maturation, and recruiting immunosuppressive cells. Here, we present a strategy to enhance CAR-T cell efficacy and reprogram the TME by engineering CAR-T cells to secrete a novel VEGF-A–neutralizing single-chain variable fragment (scFv). We demonstrate that scFv-secreting CAR-T cells (CAR-αVEGF T cells) achieve superior anti-tumor efficacy against models of ovarian cancer and brain cancer compared to conventional CAR-T cells that do not secret anti–VEGF-A scFvs. Notably, the enhanced efficacy exhibited by CAR-αVEGF T cells is not replicated by combining conventional CAR-T cells with anti-VEGF antibody therapy. Mechanistically, treatment with CAR-αVEGF T cells reduces or reverses multiple adverse effects associated with on-target CAR-T cell therapy, including intra-tumoral infiltration of myeloid cells, exaggerated vasculature abnormalities, and hypoxia. Treatment with CAR-αVEGF T cells also results in an enrichment of immune-stimulatory and anti-tumor signatures among intra-tumoral immune cells. These findings indicate that blocking of intra-tumoral VEGF by αVEGF-scFv armored CAR-T cells enable favorable remodeling of the immunosuppressive TME, resulting in more potent CAR-T cell therapies. Citation Format: Torahito A Gao, Justin D Clubb, Ryan M Shih, Tanya Singh, Gabriella Dibernardo, Amanda Shafer, Amber Bouren, Melanie A Ceja, Sophie Ong, Christine Brown, Hideho Okada, Sanaz Memarzadeh, Han-Chung Wu, Yvonne Y Chen. VEGF-neutralization by armored CAR-T cells remodel the tumor microenvironment and enhance antitumor efficacy against solid tumors [abstract]. In: Proceedings of the AACR IO Conference: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2025 Feb 23-26; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(2 Suppl):Abstract nr A023.

Year:

2025

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Debra Bourne

Assistant Professor

University of Kentucky

UNITED STATES
View details

Ziqian Yang

Johns Hopkins University

UNITED STATES
View details

Ying-Tzu Yen

UCLA Health

UNITED STATES
View details

Ajit S Divakaruni

-

UNITED STATES
View details

Yvonne Y. Chen

Professor

University of California

UNITED STATES
View details

Sungyong You

Professor

Cedars-Sinai Medical Center

UNITED STATES
View details